Dimerix (ASX:DXB) has reached a significant milestone in its late-stage clinical program, announcing that its global ACTION3 Phase 3 trial of DMX-200 for focal segmental glomerulosclerosis has now completed recruitment and dosing of its target 286 adult patients. …
Dimerix completes adult recruitment in Phase 3 trial for FSGS treatment DMX-200
December 15, 2025 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
Australians turn to local pharmacies as frontline of everyday healthcare
March 13, 2026 - - Latest News -
Sandoz and Camp Quality unite to strengthen support for Australian families facing childhood cancer
March 13, 2026 - - Latest News -
The leadership challenge behind Australia’s medicine access gap
March 13, 2026 - - Latest News -
Australia has spent four decades having the wrong conversation about medicines access
March 13, 2026 - - Latest News -
‘An absolute medical miracle’ - MPs highlight progress and challenges at Cystic Fibrosis event
March 13, 2026 - - Latest News -
Australia’s top community pharmacists honoured at national awards
March 13, 2026 - - Latest News -
A new prostate cancer technology moves closer to global trials after strong early results
March 12, 2026 - - Australian Biotech